Analysis reportAll specifications met
CJC-1295 (no DAC) + Ipamorelin 10mg
Peptide Stock ref. PSV-2610-CP10-01
Purity99.55%RP-HPLC, UV 214 nm, per component
Content per vial10.57 mg105.7% of 10 mg label claim
IdentityConfirmedLC-MS (ESI+)
Test results
| Test | Specification | Result | Outcome |
|---|---|---|---|
| Identity (LC-MS): CJC-1295 no DAC | Within ±1 Da of 3367.954 Da | 3367.892 Da | Pass |
| Identity (LC-MS): Ipamorelin | Within ±1 Da of 711.868 Da | 711.651 Da | Pass |
| Purity (RP-HPLC 214 nm): CJC-1295 no DAC | ≥ 99.25% | 99.52% | Pass |
| Purity (RP-HPLC 214 nm): Ipamorelin | ≥ 99.25% | 99.58% | Pass |
| Content: CJC-1295 no DAC | 4.5–5.5 mg | 5.27 mg | Pass |
| Content: Ipamorelin | 4.5–5.5 mg | 5.3 mg | Pass |
| Net peptide content | CJC-1295 5 mg + Ipamorelin 5 mg | 10.57 mg (105.7% of claim) | Pass |
| Sterility (rapid PCR) | No microbial DNA detected | Not detected | Pass |
About this report
- Sample received by the lab 6 October 2026; report issued 11 October 2026.
- 1 vial tested.
- Appearance as received: white lyophilised powder.
- Results relate to the sample tested. For laboratory research use only.